| 5R01AG062687-04 |
2022 |
$684780 |
(-)-Phenserine inhibition of neuronal death in Alzheimer’s disease and developing brain-labeled plasma exosomes assays as biomarkers for a phenserine phase 1b ascending dose trial |
| 5R01AG062687-03 |
2021 |
$695025 |
(-)-Phenserine inhibition of neuronal death in Alzheimer’s disease and developing brain-labeled plasma exosomes assays as biomarkers for a phenserine phase 1b ascending dose trial |
| 5R01AG062687-02 |
2020 |
$702380 |
(-)-Phenserine inhibition of neuronal death in Alzheimer's disease and developing brain-labeled plasma exosomes assays as biomarkers for a phenserine phase 1b ascending dose trial |
| 1R01AG062687-01 |
2019 |
$725263 |
(-)-Phenserine inhibition of neuronal death in Alzheimer?s disease and developing brain-labeled plasma exosomes assays as biomarkers for a phenserine phase 1b ascending dose trial |
| 3R01AG062687-01S1 |
2019 |
$324832 |
(-)-Phenserine inhibition of neuronal death in Alzheimer?s disease and developing brain-labeled plasma exosomes assays as biomarkers for a phenserine phase 1b ascending dose trial |
